drugset / Trial / NCT06246695

A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers

NCT06246695

Phase 1 Completed 40 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study was to assess the effect of rifampicin and itraconazole, on the pharmacokinetics (PK) of Jaktinib in healthy Volunteers.

Timeline

Start
2021-10-27
Primary completion
2022-01-12
Completion
2022-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject Jaktinib Unknown 100 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.